Altimmune Inc (NASDAQ: ALT) on Tuesday, plunged -4.98% from the previous trading day, before settling in for the closing price of $6.43. Within the past 52 weeks, ALT’s price has moved between $5.28 and $14.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 154.97% over the past five years. The company achieved an average annual earnings per share of 18.75%. With a float of $70.39 million, this company’s outstanding shares have now reached $71.12 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -3857.69%, operating margin of -191365.38%, and the pretax margin is -199076.92%.
Altimmune Inc (ALT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Altimmune Inc is 1.03%, while institutional ownership is 57.47%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.
Altimmune Inc (ALT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.36% during the next five years compared to 35.74% growth over the previous five years of trading.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Altimmune Inc (ALT) is currently performing well based on its current performance indicators. A quick ratio of 16.87 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8691.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Altimmune Inc (NASDAQ: ALT) saw its 5-day average volume 2.3 million, a positive change from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 32.62%. Additionally, its Average True Range was 0.40.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 4.72%, which indicates a significant decrease from 7.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.84% in the past 14 days, which was lower than the 76.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.18, while its 200-day Moving Average is $7.11. Nevertheless, the first resistance level for the watch stands at $6.37 in the near term. At $6.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.80. If the price goes on to break the first support level at $5.94, it is likely to go to the next support level at $5.77. Assuming the price breaks the second support level, the third support level stands at $5.51.
Altimmune Inc (NASDAQ: ALT) Key Stats
Market capitalization of the company is 434.57 million based on 71,125K outstanding shares. Right now, sales total 430 K and income totals -88,450 K. The company made 10 K in profit during its latest quarter, and -22,850 K in sales during its previous quarter.
